Q-omics provides the consensus-scored MCTS2P profile across patient tissues and cancer cell-line models. MCTS2P expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, MCTS2P is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, MCTS2P RNA expression shows 20,168 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight READ, COAD, and THYM as cancer lineages where MCTS2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MCTS2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MCTS2P survival associations across molecular data types. MCTS2P RNA expression shows survival associations in the most cancer types (27), followed by mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MCTS2P RNA expression–survival associations across cancer types. High MCTS2P expression shows unfavorable associations in CESC, UCS, UCEC and KICH, but favorable associations in READ and COAD. The READ Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for MCTS2P RNA expression.
This table summarizes MCTS2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MCTS2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MCTS2P shows lower tumor expression in THCA and higher tumor expression in COAD, BLCA, HNSC, LUAD and LUSC. The COAD box plot shows higher MCTS2P RNA expression in tumor versus normal tissue (log2 FC = +1.700, t-test p < 0.001).
This table shows molecular features associated with MCTS2P in patient tissues and cancer cell lines. In patient samples, MCTS2P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
